10x Genomics, Inc. (TXG)

Every figure this model derived for TXG, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 5,649,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 552,033,000 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-06-30
current assets 674,671,000 AssetsCurrent 2026-06-30
current liabilities 118,509,000 LiabilitiesCurrent 2026-06-30
equity 825,546,000 StockholdersEquity 2026-06-30
interest expense 0 InterestExpenseNonoperating 2025-12-31
ocf 127,085,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 616,911,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 98,741,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TXG on one particular measure came for.

RatioValue
cash operating margin8.16
current ratio7.11
current ratio reported5.69
deferred revenue growth10.08
dilution pct3.57
fcf margin19.68
growth cv1.28
operating margin-14.33
owner earnings margin3.68
revenue growth-4.28
revenue growth per share-7.58
roic-25.53
rpo growth3.61
rule of 40-18.6
sbc pct revenue16.01

What to be careful about

What this model itself distrusts about TXG's figures. Written by the derivation as it ran, not added afterwards.